Some of the trials information should be made public this quarter. Some people forget easiy...or conveniently....LABS stated they cannot dislcose much for "competitive reason" including the name of their global pharma partner but did say that Q4 disclosure of their Brazil pharma partner name is a possibility once ANVISA approves their submission.
I guess some people just don't get it when it comes to secrecy for competitive reasons but just whine continually on the same topic.
I wonder, is there a cannabinoid or combination there of to improve memory performance?
With the right products being approved, North America or internationally, this stock could reach over $8 by the holiday season but those approvals are based on government health agencies and so too the timing of them.
FDA drug monograph, ANDA, NDA, 505(b), multiple approvals pending by ANVISA as well.